Effects of losartan and chlorthalidone on blood pressure and renal vascular resistance index in non-diabetic patients with essential hypertension and normal renal function

Journal of Cardiovascular Pharmacology

Volumn 44, Issue 5, 2004, Pages 520-524

  Caruso, D ^a   D'Avino, M ^a   Acampora, C ^a   Romano, L ^a   Bevilacqua, N ^a   Caruso, G ^a   Degli Esposti, D ^b   Borghi, C ^b,c  

^a CARDARELLI HOSPITAL   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Chlorthalidone; Hypertension; Kidney protection; Losartan

Indexed keywords

CHLORTALIDONE; LOSARTAN;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFECT; DRUG EFFICACY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; KIDNEY VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADULT; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CHLORTHALIDONE; CROSS-OVER STUDIES; DATA INTERPRETATION, STATISTICAL; DRUG ADMINISTRATION SCHEDULE; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; KIDNEY CORTEX; KIDNEY FUNCTION TESTS; LOSARTAN; MALE; MIDDLE AGED; RENAL CIRCULATION; SINGLE-BLIND METHOD; TIME FACTORS; TREATMENT OUTCOME; VASCULAR RESISTANCE;

EID: 7444270482     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200411000-00002     Document Type: Article

References (36)

1. Ruilope LM, Lahera V, Rodicio JL, et al. Are renal hemodynamics a key factor in the development and maintenance of arterial hypertension in humans? Hypertension. 1994;23:3-9.
2. Wright JT, Bakris G, Greene T, et al. for the African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney diseases: results from the AASK Trial. JAMA. 2002;288:2421-2431.
3. Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin II-converting-enzyme inhibitor in non diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet. 2003;361:117-124. RT
4. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
5. Perry HM Jr, Miller JP, Fornoff JR. Early predictors of 15 year end stage renal disease in hypertensive patients. Hypertension. 1995;25:587-594.
6. Klag MJ, Whelton JP, Randall BL. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334:13-18.
7. Klag MJ, Whelton PK, Randall BL. End stage renal disease in African-American and white men. 16 year MRFIT findings. JAMA. 1997;2777:1293-1298.
8. Perneger TV, Whelton PK, Klag MJ. History of hypertension in patients treated for end-stage renal disease. J Hypertens. 1997;15:451-456.
9. Whelton PK, He J, Perneger TV, et al. Kidney damage in "benign" essential hypertension. Curr Opin Nephrol Hyp. 1997;6:177-183.
10. Whelton PK, Perneger TV, He J, et al. The role of blood pressure as a risk factor for renal disease: a review of the epidemiologic evidence. J Hum Hypertens. 1996;22:164-173.
11. Walker WG. Hypertension-related renal injury: a major contributor to end stage renal disease. Am J Kidney Dis. 1993;22:164-173.
12. Ruilope LM, Campo C, et al. Blood pressure and renal function: therapeutic implications. J Hypertens. 1996;14:1259-1263.
13. Maki DD, Ma JZ, Louis TA, et al. Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med. 1995;155:1073-1080.
14. Preston RA, Singer I, Epstein M. Renal parenchymal hypertension: current concepts of pathogenesis and management. Arch Intern Med. 1996;154:637-642.
15. Preston RA, Epstein M. Hypertension and renal parenchymal disease. Semin Nephrol. 1995;15:138-151.
16. Krumme W, Blum V, Schwertfegher E, et al. Diagnosis of renovascular disease by intra and extrarenal Doppler scanning. Kidney Int. 1996;50:1288-1292.
17. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint Reduction in hypertension study (LIFE); a randomised trial against atenolol. Lancet. 2002;359:1004-1010.
18. Laverman GD, Remuzzi G, Ruggenenti P. ACE inhibition versus angiotensin receptor blockade: which is better for renal and cardiovascular protection? J Am Soc Nephrol. 2004;15(Suppl 1):S64-70.
19. Greco BA, Breyer JA. Atherosclerotic ischemic renal disease. Am J Kidney Dis. 1997;29:67-187.
20. Simonsen MS, Dunn MJ. Endothelin peptides and the kidney. Ann Rev Physiol. 1999;55:249-265.
21. Perico N, Remuzzi G. Role of endothelin in glomerular injury. Kidney Int. 1993;43(Suppl 39):S76-S80.
22. Clozel M, Breu V, Burri K. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature. 1993;365:259-261.
23. Clozel M, Breu V, Gray GA, et al. Pharmacology of Ro 46-2005, the first synthetic nonpeptide endothelin receptor antagonist: implications for endothelin physiology. J Cardiovasc Pharmacol. 1993;22(Suppl 8):s337.
24. Nakamura Y, Hidehiko O, Xiaoyan ED. Angiotensin type 1 receptor antagonism and ACE inhibition produce similar renoprotection in N £-nitro 1>-arginine methyl ester7spontaneously hypertensive rats. Hypertension. 2001;37:1262-1265.
25. Nakamura T, Obata JE, Kimura H, et al. Blocking angiotensin II ameliorates proteinuria and glomerular lesions in mesangioproliferative glomerulonephritis. Kidney Int. 1999;55:877-889.
26. Francischetti A, Ono H, Froelich ED. Renoprotective effects of felodipine and/or enalapril in spontaneously hypertensive rats with or without L-NAME. Hypertension. 1998;31:795-801.
27. Chan JNC, Critchley JAJH, Tomlinson B. Anti-hypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin-dependent diabetes mellitus. Am J Nephrol. 1997;17:22-80.
28. Ziai F, Ots M, Provost AP. The angiotensin receptor antagonist, irbesartan, reduces renal injury in experimental chronic renal failure. Kidney Int. 1996;50(Suppl 57):S132-S316.
29. Kohzuki M, Yasujima M, Liu PF. Cardiovascular and renal protective effects of losartan in spontaneously hypertensive rats with diabetes mellitus. Clin Exp Pharmacol Physiol 1995;11:S336-S367.
30. Gansevoort RT, de Zeeuw D, Shahinfar S. Effect of the angiotensin II antagonist losartan in hypertensive patients with renal disease. J Hypertens. 1994;12(Suppl):S37-S42.
31. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
32. Noda M, Fukuda R, Matsuo T, et al. Effects of candesartan cilexetil (TCV 116) and enalapril in 5/6 nephrectomized rat. Kidney Int. 1997;63:S136-S139.
33. Noda M, Matsuo T, Fukuda R, et al. Effects of candesartan cilexetil (TCV116) in rats with chronic renal failure. Kidney Int. 1999;56:898-909.
34. Nakajima M, Hutchinsson HG, Fjinaga M, et al. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci USA. 1995;92:10663-10667.
35. Stoll M, Steckelings UM, Paul M, et al. The angiotensin AT2 receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest. 1995;95:6561-6657.
36. Tsuzuki S, Matoba T, Eguchi S, et al. Angiotensin II type 2 receptor inhibits cell proliferation and activates tyrosine phosphatase. Hypertension. 1996;28:916-918.